Drug repurposing for chemical agent exposure

HHS's Biomedical Advanced Research and Development Authority (BARDA) wanted to identify commonly available drugs -- obtainable from hospitals, pharmacies, and the community -- that could serve as Medical Countermeasures (MCMs) against chemical exposure. Clarivate applied its proprietary knowledge graph (spanning Cortellis Drug Discovery Intelligence and MetaBase) with omics-driven and symptom-based approaches to identify "proxy" indications, prioritize gene targets, and reconstruct mechanistic pathway links between candidate drugs and chemical-exposure pathology. The work produced a target-prioritization framework for chemical exposure agents despite a dearth of research data, and informed public emergency-policy recommendations on accessible drugs to counter pulmonary and hematological toxicity from chlorine gas and sulfur mustard. Clarivate states the BARDA partnership led to "actionable repurposing strategies" for chemical-exposure countermeasures.

Clarivate owns Cortellis, the curated competitive-intelligence and pipeline-tracking platform standard in pharma portfolio-management teams.

This sits in the Data Providers stage of the AI use-case lifecycle: Named examples from the real-world-data, claims and competitive-intelligence providers pharma AI systems are trained on, benchmarked against, or run inside of.